Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

Cosmo Fowler, M.D., from Emory University in Atlanta, and colleagues examined data from the TriNetX U.S. Collaborative Network to examine whether OSA modifies outcomes in patients with T2DM receiving ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...

Studies combing through past patient data have made a similar link between drugs like Ozempic and a loss of appetite for more than just food.

Weight loss surgery offers lasting results that go beyond reducing body weight. It helps improve diabetes control, supports ...

A 70-year-old woman developed severe reflux oesophagitis and ulceration after months of semaglutide use, highlighting the ...

Pharmaceutical company Novo Nordisk is working on an Ozempic-style semaglutide tablet just for weight loss, and early results ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.